| Time | Agenda | |
| 09:00 - 09:30 | Registration | |
| 09:30 - 09:35 | Welcome Remarks｜ Han-Chung Wu 吳漢忠 | |
| 09:35 - 09:40 | Moderator｜ Andrew H.-J. Wang 王惠鈞 | |
| 09:40 - 10:20 |
《Developing Antibodies Targeting LILRB2/TREM2 in Alzheimer′s Disease》 Zhiqiang An 安志強 Director, Texas Therapeutics Institute at the Brown Foundation Institute of Molecular Medicine |
|
| 10:20 - 10:35 | Break | |
| 10:35 - 10:40 | Moderator｜ Tse-Wen Chang 張子文 | |
| 10:40 - 11:20 |
《Ab+1: New Trend in Antibody-related Drug Design》 Jeng Her 何正宏 Chief Executive Officer (CEO), AP Biosciences, INC. |
|
| 11:20 - 12:00 |
《Innovative Technologies to Expedite Global Biologics Development & Manufacturing》 Weichang Zhou Honorary President and Senior Advisor to (CEO), WuXi Biologics |
|
| 12:00 - 13:30 | Lunch Seminar | |
| 13:30 - 13:35 | 4th TAA General Assembly | |
| 13:35 - 13:40 | Moderator｜ Woei-Jer Chuang 莊偉哲 | |
| 13:40 - 14:20 |
《Technology to Generate Highly Functional Antibodies for Antibody Drug Development》 Haruhiko Kamada 鎌田 春彥 Group Leader, Laboratory of Advanced Biopharmaceuticals / Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Japan |
|
| 14:20 - 15:00 |
《OBI-992: An Anti-TROP2 ADC with Distinct Properties》 Ming-Tain Lai 賴明添 Chief Scientific Officer (CSO), OBI Pharma, INC. |
|
| 15:00 - 15:25 | Break | |
| 15:25 - 15:30 | Moderator｜ Margaret Dah-Tsyr Chang 張大慈 | |
| 15:30 - 16:10 |
《Gene Therapies for the Brain》 Wuh-Liang Hwu 胡務亮 Professor, Department of Medical Genetics and Pediatrics,National Taiwan University Hospital |
|
| 16:10 - 16:50 |
《Degrader-Antibody Conjugates: Emerging Modality for Tissue-Specific Targeted Therapy》 Shu-Jen Chen 陳淑貞 Chief Scientific Officer (CSO), AnHorn Medicines, INC. |
|
| 16:50 - 17:00 | Closing Remarks | |
| Time | Agenda | |
| 08:30 - 09:00 | Registration | |
| 09:00 - 09:05 | Welcome Remarks｜ Wen-Chang Chang 張文昌 | |
| 09:05 - 09:10 | Moderator｜ Alice Lin-Tsing Yu 陳鈴津 | |
| 09:10 - 09:40 |
《Perspectives of Precision Lung Cancer Control in Taiwan》 Pan-Chyr Yang 楊泮池 Academician, Academia Sinica / Professor, Department of Internal Medicine, National Taiwan University |
|
| 09:40 - 10:10 |
《My 50+ Years of DNA Exploration》 Andrew H.-J. Wang 王惠鈞 Academician, Academia Sinica |
|
| 10:10 - 10:40 |
《Clinical Development of Antibody Therapies Past, Present, and Future》 Yun Yen 閻 雲 Joint Appointment Research Fellow, Institute of Biological Chemistry, Academia Sinica |
|
| 10:40 - 10:55 | Break | |
| 10:55 - 11:00 | Moderator｜ Chung-Hsuan Chen 陳仲瑄 | |
| 11:00 - 11:30 |
《Strategies to Ensure the Genomic Integrity of CRISPR-Cas9 Edited Cells in the Era of Precision Medicine》 John Yu 游正博 Director, The Institute of Stem Cell and Translational Cancer Research (ISCTCR), Chang Gung Memorial Hospital (CGMH) |
|
| 11:30 - 12:00 |
《Immunometabolism as a Therapeutic Target for Metabolic Disorders》 Chih-Hao Lee 李志浩 Director, Genomics Research Center, Academia Sinica |
|
| 12:00 - 12:05 | Closing Remarks｜ Han-Chung Wu 吳漢忠 | |
| 14:00 - 17:00 | Workshop｜Antibody Drug Discovery: From Target to Lead (Additional Fee Required) | |
Organizers
Co-Organizers
Supporting Organizers
Sponsors
